October 06, 2022
Will Manufacturing Be the Stumbling Block for T-Cell Therapies?
Related News
-
June 15, 2026Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners Investment
-
June 10, 2026
Cellares Joins New American Industrial Alliance, Advancing U.S. Biopharmaceutical Manufacturing Independence
-
June 09, 2026
Cathie Wood’s ARK Invest Joins Cellares’ $277 Million Series D
